Sanford C. Bernstein Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by equities researchers at Sanford C. Bernstein from $1,110.00 to $1,070.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price objective suggests a potential upside of 45.86% from the company’s previous close.

Several other equities analysts also recently commented on REGN. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,044.48.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $733.59 on Tuesday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $756.46 and a 200 day simple moving average of $966.75. Regeneron Pharmaceuticals has a 1-year low of $693.00 and a 1-year high of $1,211.20. The stock has a market cap of $80.61 billion, a P/E ratio of 18.15, a PEG ratio of 2.19 and a beta of 0.10.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the period. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter worth $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $37,000. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $39,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.